Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A method of preparing a suspension of cells of the zona glomerulosa from rat adrenal capsules treated with crude collagenase is described. The cells responded to ACTH, angiotensin II and serotonin by increased production of aldosterone. Pooled human sera or individual human sera (from healthy normal or non-psychiatric in-patients) to a final concentration of 30% had no effect on ACTH-stimulated production of aldosterone. Many serum samples from five patients with manic-depressive psychosis, however, caused a reduction in aldosterone production; 65% of those samples taken during depression, 44% of the samples taken during manic episodes and 23% of the samples taken when the mood was normal. Sera from manic-depressive patients also reduced the production of aldosterone caused by angiotensin II or serotonin. This effect of serum from manic-depressives in vitro may be related to the abnormalities of aldosterone control in such patients.
 ...
PMID:Inhibition of aldosterone production in adrenal cell suspensions by serum from patients with manic-depressive psychosis. 21 27

Onset of mania was evaluated retrospectively in 48 bipolar manic-depressive patients. Mania occurred as the initial episode in 40% of cases. In patients with initial episode of depression, approximately 80% developed mania prior to their third episodes of depression and within 5 years from the onset of this illness. Differences in type of illness onset were related to family history of bipolar illness and sex of the proband. Male patients with a positive family history were significantly more likely to manifest mania at onset of illness.
 ...
PMID:Onset of mania in bipolar manic-depressive patients. 28 68

Lithium carbonate has established itself as an effective therapeutic agent in primary affective disorders. As not all the patients with primary affective disorders respond to lithium therapy, it is necessary to identify responders prior to treatment. The important indicators of favourable lithium response include a definitive diagnosis of primary affective disorder, occurrence of less than four episodes of mania and depression within one year, psychotic features during both manic as well as depressive episodes, "grandiose-elated" picture during manic episodes; a family history of bipolar illness and response of affected family members to lithium treatment. While those with more than four episodes are not likely to respond to lithium therapy, those with episodes less frequent than once a year or two may not need prophylactic lithium. Among the depressed, hypersomnic depressed patients respond to lithium combined with a monoamine oxidase inhibitor. In addition to clinical predictors of response to lithium treatment, there are a number of pharmacokinetic, neurophysiological and biochemical indices which have been employed as supplementary predictors of response to lithium therapy.
 ...
PMID:Prediction of lithium response in affective disorders. 34 5

Patients diagnosed as suffering from manic-depressive psychosis-depressed (ICD 296.2) were retained and randomly assigned to two groups, one receiving mianserin, the other placebo. For the pre-trial period and throughout the trial, patients' sleep was estimated by themselves and by nurses. Patients rated themselves on the Beck Self-Rating Inventory (BSRI) before the trial and at weekly intervals thereafter. Nurses rated the patients twice daily on a seven-point global rating scale of depression. A blood sample for estimation of mianserin levels was taken on day 14. Eighteen patients received placebo and 21 mianserin. On the BSRI, the mianserin group improved significantly, whereas the placebo group showed no change. The mean daily nurse ratings showed some improvement in the placebo group, but a greater improvement in the mianserin group, particularly towards the end of the 14 days. Sleep (nurses' observations) improved significantly in the mianserin group from the first night of the trial and over the following 2 weeks. Sleep as assessed by the patients also improved significantly on mianserin. Blood levels of mianserin did not correlate significantly with changes in mood or sleep. This study confirms that mianserin is an antidepressant. The mianserin group showed an improvement in sleep which, since it started from the first night of the trial, was probably due to the hypnotic sedative properties of the drug.
 ...
PMID:The antidepressant properties of mianserin and its effect on sleep. 37 85

Lithium salts have been widely used for several years in the treatment of manic-depressive psychosis. Various side-effects of lithium salts have been described. The present case report present two patients in whom sinus node dysfunction leading to syncope was caused by lithium. One of the cases showed signs of depressed sinus node function even when not on lithium, but no symptoms arose until lithium treatment was commenced. The second case showed no signs of depressed sinus node function when lithium was withdrawn. To study the prevalence of sinus node dysfunction in patients on lithium therapy, 97 consecutive patients on lithium were examined. The examination included case history, ECG and carotid massage. In two patients lithium could not be ruled out as being responsible for sinus node depression and in one patient the same was true for the atrioventricular node. None of these patients had any symptoms. It is concluded that lithium treatment may result in sinus node dysfunction. This side-effect is, however, not common. Lithium treatment can obviously be instituted in all patients without a history suggesting sinus node dysfunction. Patients with a history of dizziness and/or syncope should not be given lithium until thorough cardiological examination has been carried out. Likewise, a cardiological examination should be performed if patients on lithium develop symptoms of this type.
 ...
PMID:Syncope caused by lithium treatment. Report on two cases and a prospective investigation of the prevalence of lithium-induced sinus node dysfunction. 37 17

Since neither the unipolar nor the bipolar theories of manic-depressive psychosis explain all its features, an alternative model was tested. The hypotheses are that mixed affective psychoses represent a superimposition on hypomania of a second type of depression which can sometimes develop from the depressive phase of manic-depressive psychosis, and that schizophrenia occurring in the course of a manic-depressive illness is an alternative to mixed affective psychosis. From an examination of the clinical histories of a random sample of people with bipolar manic-depressive psychosis, evidence was found to support both ideas.
 ...
PMID:Mixed affective states and the natural history of manic-depressive psychosis. 42 31

This first part of a multiphase longitudinal study looks at life events implicated in manic depression among an American working class, bipolar sample. Three turning points are identified. a) Stressful life events occurred that resulted in loss of significant social roles. b) Attempts to regain or replace the roles or otherwise "fight back" proved ineffective. c) Retreat via depression, and rebellion via mania, ensued. These turning points were well verified for 75 per cent of the subjects prior to first onset, and for 56 per cent prior to most recent onset. Special methodological issues are raised, and the need for a biopsychosocial etiology of manic depression is suggested.
 ...
PMID:Role loss and working-class manic depression. 47 65

Twelve acute depressed patients were studied in the course of antidepressant treatment. Three-day-24-hour urine samples for 3-methoxy-4-hydroxy-phenylglycol (MHPG) were collected both before and after a five week treatment schedule. MHPG were estimated by spectrophotometry. Initial MHPG excretion did not reflect the severity of pretreatment depression and final MHPG showed no specific correlation with post-treatment improvement. No specific or uniform influence of different anti-depressant treatments or changes in MHPG was evident. Depressed patients with bipolar affective disorder tend to have initially lower MHPG levels than patients with unipolar depression. Urinary MHPG excretion measurements may prove not to be a useful index in the diagnosis and choice of treatment in patients suffering from primary depression.
 ...
PMID:Urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) excretion in depression. 48 Jun 80

Results of the present study provide evidence of: 1) a positive association between bipolar affective disorder and blood type O and a corresponding negative association between the former and blood type A, 2) a positive association between unipolar affective disorder and blood type O, and 3) a positive association between involutional depression and blood type A and a corresponding negative association between the former and blood types B and O. Sex does not appear to modify the ABO blood types' distribution in patients with bipolar, unipolar affective disorder, or involutional depression, and the same holds for early- or late-onset of the illness in patients with bipolar or unipolar affective disorders. Findings in the present study do not support the validity of the bipolar-unipolar distinction of affective disorders, and provide evidence in favour of the view that involutional depression is a genetically distinct nosological entity.
 ...
PMID:Affective disorders and ABO blood types. 49 68

Steady state intravenous tyramine dose pressor-response tests were administered to a patient with bipolar illness during depressed and hypomanic phases of her illness. The greatest tyramine sensitivity while unmedicated occurred when the patient was hypomanic, and the least sensitivity when she was depressed before her first switch. The data raise the possibility that changes in peripheral alpha-adrenergic receptor sensitivity accompany spontaneous mood cycles. Tyramine produced a replicable mood and cognitive alteration only in the infusion closest to the switch from hypomania to depression, suggesting that the CNS may be particularly susceptible to peripheral noradrenergic inputs at specific points in bipolar illness.
 ...
PMID:Tyramine infusions in bipolar illness: behavioral effects and longitudinal changes in pressor sensitivity. 49 1


1 2 3 4 5 6 7 8 9 10 Next >>